Gut microbiota shaping fatty liver disease progression
Life Science Alliance · 2027
DOI: 10.26508/lsa.202603756 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life Science Alliance, 2027. Verfasst von Martyna Wysokińska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Fatty Liver. Die Arbeit nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency, European Molecular Biology Organization.
Abstract (Originalsprache)
The gut–liver axis is an important regulator of homeostasis, and its dysregulation has been implicated in the pathogenesis of metabolic dysfunction–associated steatotic liver disease (MASLD). In this review, we summarize current knowledge on both compositional alterations of the gut microbiome in MASLD and the functional consequences of these changes. We first discuss changes across major microbial domains, including bacteria, archaea, eukaryota, and bacteriophages, and then focus on microbiota-derived metabolites, such as short-chain fatty acids, trimethylamine and its derivative trimethylamine N-oxide, tryptophan-derived indoles, secondary bile acids, and other bioactive compounds. Their complex impacts on intestinal barrier integrity, inflammation, lipid and glucose metabolism, and immune and hormonal signaling in the liver are highlighted. We further examine mechanisms involving the translocation of microbial products and the modulation of nuclear and membrane receptors. Finally, we outline current challenges and knowledge gaps that need to be addressed to better understand the role of the gut microbiota in MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland.
- Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland akolodziejczyk@iimcb.gov.pl.
ORCID-Profile: Martyna Wysokińska, Marta Mysza, Aleksandra E Uryga, Aleksandra A Kołodziejczyk
Förderung
- Medical Research Agency
- European Molecular Biology Organization
Zitieren
APA
Wysokińska, M., Mysza, M., Uryga, A. E., & Kołodziejczyk, A. A. (2027). Gut microbiota shaping fatty liver disease progression. Life Science Alliance. https://doi.org/10.26508/lsa.202603756
Vancouver
Wysokińska M, Mysza M, Uryga AE, Kołodziejczyk AA. Gut microbiota shaping fatty liver disease progression. Life Science Alliance. 2027. doi:10.26508/lsa.202603756
BibTeX
@article{Wysokiska2027,
author = {Wysokińska, Martyna and Mysza, Marta and Uryga, Aleksandra E and Kołodziejczyk, Aleksandra A},
title = {Gut microbiota shaping fatty liver disease progression},
journal = {Life Science Alliance},
year = {2027},
doi = {10.26508/lsa.202603756}
}
EUVIMED